menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Gilead`s Seladelpar Gets EU Conditional Nod For Biliary Cholangitis

    BUSINESSWIRE

    Gilead`s Seladelpar Receives CHMP Nod For Biliary Cholangitis

    BUSINESSWIRE

    Gilead’s Livdelzi Shows Sustained Efficacy in Biliary Cholangitis

    BUSINESSWIRE

    FDA approval of Livdelzi, Gilead launches an inflammatory drug for first time

    FIERCE PHARMA

    Orsini Now Dispensing Livdelzi (seladelpar), for Treatment of Rare Liver Disease

    PR NEWSWIRE

    Gilead shows $4.3B liver drug improves outcomes out to 2 years

    FIERCE BIOTECH

    Gilead: Seladelpar Sustained Efficacy/Safety Profile In PBC

    BUSINESSWIRE

    Gilead liver disease med still delivers ahead of FDA verdict

    FIERCE BIOTECH

    Seladelpar Shows Liver, Itch Improvements In PBC

    BUSINESSWIRE

    The New England Journal Publishes Positive Phase 3 of CymaBay`s Seladelpar

    PR NEWSWIRE

    Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

    PRESS RELEASE

    CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar

    PR NEWSWIRE

    Published Data Showes Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement

    PR NEWSWIRE

    CymaBay Submits NDA for Seladelpar for Treatment of Primary Biliary Cholangitis

    PR NEWSWIRE

    CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results

    PR NEWSWIRE

    CymaBay Announces Publication of Two-year Safety Results of Seladelpar

    GLOBENEWSWIRE

    Seladelpar Granted Breakthrough Therapy Designation for Biliary Cholangitis

    GLOBENEWSWIRE

    CymaBay™s Ph 3 Data Evaluating Seladelpar for Biliary Cholangitis to be Featured

    GLOBENEWSWIRE

    CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar

    GLOBENEWSWIRE

    CymaBay`s Seladelpar Achieves Significance in Phase 3 in Biliary Cholangitis

    PR NEWSWIRE

    CymaBay Initiates Phase 3 Placebo-Controlled, Randomized Study of Seladelpar

    PR NEWSWIRE

    CymaBay Announces Publication of Results FromENHANCE, Ph 3 Study of Seladelpar

    GLOBENEWSWIRE

    CymaBay Tx to Publish Results From 52-Week Phase 2 Study of Seladelpar in PBC

    GLOBENEWSWIRE

    Bon Secours Liver Institute of Richmond Participating in RESPONSE Study

    GLOBENEWSWIRE

    Liver Institute NW Participating in RESPONSE, a Global Phase 3 Research Study

    GLOBENEWSWIRE

    CymaBay Announces Presentations at International Liver Congress 2021

    GLOBENEWSWIRE

    CymaBay Therapeutics to Present Data from its Ph2 Study of Seladelpar

    GLOBENEWSWIRE

    FDA lifts hold on CymaBay’s NASH drug, but the company may still leave the ailing field

    ENDPTS

    Genfit goes to China with a deal worth up to $228M for NASH drug

    ENDPTS

    NASH contender CymaBay runs into trouble as mid-stage data disappoint

    ENDPTS

    CymaBay Therapeutics` Seladelpar FDA Breakthrough Therapy Designated

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.